Are glucocorticoids DMARDs?

被引：27

作者：

Bijlsma, Johannes W. J. ^{[1
]}

Hoes, Jos N. ^{[1
]}

Van Everdingen, Amalia A. ^{[1
]}

Verstappen, Suzan M. M. ^{[1
]}

Jacobs, Johannes W. G. ^{[1
]}

机构：

[1] Univ Utrecht, Med Ctr, Dept Rheumatol & Clin Immunol, NL-3508 GA Utrecht, Netherlands

来源：

BASIC AND CLINICAL ASPECTS OF NEUROENDOCRINE IMMUNOLOGY IN RHEUMATIC DISEASES | 2006年 / 1069卷

关键词：

glucocorticoids; DMARDs; rheumatoid arthritis; erosions; prednisone;

D O I：

10.1196/annals.1351.025

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Disease modifying antirheumatic drugs (DMARDs) are drugs used in rheumatoid arthritis (RA) to control the disease and to limit joint damage and improve long-term outcome. The last decade evidence has accumulated that suggests that low dosages of glucocorticoids are indeed able to control the disease and limit the destruction. This role is especially present in early disease and in combination with other drugs. The evidence is carefully evaluated and discussed. The ultimate conclusion is that indeed glucocorticoids are DMARDs and are especially useful in early RA.

引用

页码：268 / 274

页数：7

共 18 条

[1] Glucocorticoids in the treatment of early and late RA [J].

Bijlsma, JWJ ;

Boers, M ;

Saag, KG ;

Furst, DE .

ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (11) :1033-1037

[2] Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis [J].

Boers, M ;

Verhoeven, AC ;

Markusse, HM ;

vandeLaar, MAFJ ;

Westhovens, R ;

vanDenderen, JC ;

vanZeben, D ;

Dijkmans, BAC ;

Peeters, AJ ;

Jacobs, P ;

vandenBrink, HR ;

Schouten, HJA ;

vanderHeijde, DMFM ;

Boonen, A ;

vanderLinden, S .

LANCET, 1997, 350 (9074) :309-318

[3] Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial [J].

Capell, HA ;

Madhok, R ;

Hunter, JA ;

Porter, D ;

Morrison, E ;

Larkin, J ;

Thomson, EA ;

Hampson, R ;

Poon, FW .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (07) :797-803

[4]

Combe B, 2005, ANN RHEUM DIS, V64, P19

[5]

Empire Rheumatism Council, 1957, ANN RHEUM DIS, V16, P277, DOI DOI 10.1136/ARD.16.3.277

[6] Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis [J].

Gerlag, DM ;

Haringman, JJ ;

Smeets, TJM ;

Zwinderman, AH ;

Kraan, MC ;

Laud, PJ ;

Morgan, S ;

Nash, AFP ;

Tak, PP .

ARTHRITIS AND RHEUMATISM, 2004, 50 (12) :3783-3791

[7] A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects [J].

Hansen, M ;

Podenphant, J ;

Florescu, A ;

Stoltenberg, M ;

Borch, A ;

Kluger, E ;

Sorensen, SF ;

Hansen, TM .

ANNALS OF THE RHEUMATIC DISEASES, 1999, 58 (11) :713-718

[8]

Hickling P, 1998, BRIT J RHEUMATOL, V37, P930

[9] Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo [J].

Jacobs, JWG ;

van Everdingen, AA ;

Verstappen, SMM ;

Bijlsma, JWJ .

ARTHRITIS AND RHEUMATISM, 2006, 54 (05) :1422-1428

[10] THE EFFECT OF GLUCOCORTICOIDS ON JOINT DESTRUCTION IN RHEUMATOID-ARTHRITIS [J].

KIRWAN, JR ;

BYRON, M ;

DIEPPE, P ;

EASTMOND, C ;

HALSEY, J ;

HICKLING, P ;

HOLLINGWORTH, P ;

JACOBY, R ;

KIRK, A ;

MORAN, C ;

REID, D ;

SWANNELL, T ;

YATES, D ;

COOPER, C ;

GEORGE, E ;

FORBES, D ;

JESSOP, J ;

WATT, I .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (03) :142-146

← 1 2 →